AU Patent

AU2020407664A1 — Fluoroalkyl-oxadiazoles and uses thereof

Assigned to Tenaya Therapeutics Inc · Expires 2022-08-18 · 4y expired

What this patent protects

Provided herein are compounds identified as inhibitors of HDAC6 activity that can be used to treat various diseases and disorders.

USPTO Abstract

Provided herein are compounds identified as inhibitors of HDAC6 activity that can be used to treat various diseases and disorders.

Drugs covered by this patent

ozanimod-hydrochloride (OZANIMOD HYDROCHLORIDE)

Patent Metadata

Patent number: AU2020407664A1
Jurisdiction: AU
Classification: —
Expires: 2022-08-18
Drug substance claim: No
Drug product claim: No
Assignee: Tenaya Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.